Departments of Molecular Biology,1 Pathology, The University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, Texas 753902
Received 6 February 2006/ Returned for modification 27 March 2006/ Accepted 17 May 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The mammary tree in adult females is composed of a luminal epithelial layer of milk-producing cells surrounded by a basal layer of myoepithelial cells that provides structural support and contractility required for milk release (18). Myoepithelial cells possess characteristics of both epithelial cells and smooth muscle (SM) cells (SMCs). They are true epithelial cells since they are derived from ectoderm, they express cytokeratins as the major component of the intermediate filament system, they form desmosomes, hemidesmosomes, and cadherin-mediated junctions, and they are permanently separated from surrounding stroma by a basement membrane. On the other hand, like SMCs, myoepithelial cells contain numerous fine filaments in their cytoplasm, express several smooth muscle structural proteins, and possess contractile ability (10, 57). Contraction of myoepithelial cells is triggered by oxytocin stimulation, resulting in the release of milk (9, 34, 36). Although numerous studies have focused on the differentiation and functions of luminal epithelial cells, little is known of the mechanisms that control the development of myoepithelial cells, and no transcription factors that control their differentiation have yet been identified.
Differentiation of SMCs is dependent on serum response factor (SRF), a MADS (MCM1, agamous, deficiens, SRF) box transcription factor that binds a DNA sequence known as a CArG [CC(A/T)6GG] box associated with smooth muscle structural genes such as the smooth muscle
-actin and myosin heavy chain genes (16, 20, 23, 27, 29, 30, 32). Members of the myocardin family of transcriptional coactivators interact with SRF and potently enhance the expression of SRF-dependent genes (7, 11, 26, 52, 54-56, 58). Myocardin is expressed specifically in cardiac and smooth muscle cells, whereas the myocardin-related transcription factors (MRTFs) MRTF-A/MAL/MKL1 and MRTF-B/MKL-2 are expressed in a wide range of cell types (4, 5, 28, 31, 42, 53).
Deletion of the Srf gene in mice results in early embryonic lethality, precluding an analysis of possible functions of Srf after birth (2). Similarly, myocardin gene knockout mice die at embryonic day 10.5 (E10.5) from an apparent failure in differentiation of SMCs (26), and MRTF-B null mice die at about E13.5 with abnormalities in SMCs within the aortic arch arteries (38). In the skeletal muscle lineage, SRF and MRTFs are important for muscle fiber growth and maturation (25).
Here we describe the phenotype of MRTF-A mutant mice. In contrast to mice lacking myocardin or MRTF-B genes, mice homozygous for a null mutation in the MRTF-A gene are viable. However, postpartum MRTF-A mutant females are unable to productively nurse their offspring. Analysis of the molecular basis of this maternal abnormality reveals an essential role of MRTF-A in sustaining differentiation and function of mammary myoepithelial cells, which are required for ejection of milk from the mammary gland during lactation. Failure in maintaining myoepithelial cell differentiation results in apoptosis of this specific cell population. We conclude that MRTF-A is a highly specific regulator of myoepithelial cell development and survival in the mammary gland and that each member of the myocardin family is dedicated to the control of smooth muscle genes in specific subsets of cells during embryogenesis and adulthood, although they may play redundant roles in certain cell types.
| MATERIALS AND METHODS |
|---|
|
|
|---|
RT-PCR. Total RNA was purified from tissues with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. For reverse transcription (RT)-PCR, total RNA was used as a template for reverse transcriptase and random hexamer primers. Primer sequences are available on request.
Immunostaining and histology. As described previously (43), the fourth pair of mammary glands was surgically dissected, fixed with Carnoys fixative (60% ethanol, 30% chloroform, 10% glacial acetic acid) for 1 h, washed with 70% ethanol and distilled water, and then stained with carmine alum staining solution (0.2% carmine, 0.5% aluminum potassium sulfatate) overnight, washed again, and cleared with xylenes for visualization of the stained lobular-alveolar structure.
Histological sectioning and staining with hematoxylin/eosin were performed according to standard techniques. For immunostaining, sections were deparaffinized in xylenes, rehydrated through graded ethanol to phosphate-buffered saline (PBS), and permeabilized in 0.3% Triton X-100 in PBS. A standard heat antigen retrieval method was applied for antibodies against cytokeratin (CK) 14, CK18, cleaved caspase 3, and proliferating cell nuclear antigen (PCNA). Nonspecific binding was blocked by 1.5% normal goat serum in PBS, and primary antibodies were applied at a 1:200 dilution in 0.1% bovine serum albumin in PBS overnight at 4°C. Sections were washed in PBS, and fluorescein- or Texas red-conjugated secondary antibody (Vector Laboratories) was applied at a 1:200 dilution in 1% normal goat serum for 1 h. Antibodies used were mouse SM
-actin antibody (clone 1A4; Sigma), rabbit cytokeratin 14 antibody (Zymed), mouse CD10 (anti-common acute lymphoblastic leukemia antigen [CALLA]) antibody (56C6; Labvision), rabbit cytokeratin 18 antibody (Santa Cruz), rabbit cleaved caspase 3 antibody (Cell Signaling), and mouse PCNA antibody (Santa Cruz).
TUNEL staining. A dead-end fluorometric terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) system was purchased from Promega (Madison, WI), and staining was performed according to the user's manual.
RNA in situ hybridization. In situ hybridization of paraffin sections was performed as described previously (52). Identical bright and dark field images were captured, and silver grains were pseudocolored red using Adobe Photoshop, after which images were superimposed.
Western blot analysis. Total protein was extracted from mammary gland tissue in radioimmunoprecipitation assay protein extraction buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, pH 7.5) supplemented with protease and phosphatase inhibitors. The samples were homogenized and subsequently incubated on ice for 30 min and centrifuged at 9,500 x g for 20 min at 4°C. Supernatants were transferred to a fresh tube, and protein concentration was measured with the bicinchoninic acid colorimetric assay (Bio-Rad). Samples (30 µg/lane) were run on sodium dodecyl sulfate-polyacrylamide gels, blotted onto polyvinylidene difluoride membranes and incubated with blocking solution (5% milk in Tris-buffered saline with 0.1% Tween 20) for 1 h. Membranes were incubated with primary antibodies (rabbit Stat3 antibody [Santa Cruz] and rabbit phospho-Stat3-Tyr705 antibody [Cell Signaling]) diluted in blocking solution overnight at 4°C, and specifically bound antibody was detected using horseradish peroxidase-conjugated secondary antibodies in conjunction with a chemiluminescent substrate (ECL; AP Biotech).
| RESULTS |
|---|
|
|
|---|
37 kb of DNA. To introduce a loss-of-function mutation in the gene, we deleted a 1.7-kb region encompassing a portion of exon 9 and all of exon 10, which encode the basic, glutamine-rich, and SAP domains (Fig. 1A). The basic domain is required for the interaction of myocardin and MRTFs with SRF, and the SAP domain confers target gene specificity (33, 52, 54, 56). Deletion of these domains results in functional inactivation of MRTF-A. The deleted genomic region was replaced with a lacZ expression cassette fused in-frame with exon 9 and a neomycin resistance gene. The targeted MRTF-A locus was identified by Southern blot analysis of genomic DNA (Fig. 1B).
|
To confirm the gene-targeting event and determine whether the mutant allele might encode truncated MRTF-A transcripts, we performed RT-PCR with mRNA isolated from hearts of adult mice of the different genotypes, using primers representing exon sequences within and surrounding the deleted region of the gene (Fig. 1C and D). These assays confirmed that the targeted exons were deleted and also showed that exon 8 was spliced to exon 12, thereby deleting the lacZ-neo cassette (Fig. 1C). Sequencing of the RT-PCR product from the mutant allele showed that this aberrant splicing event caused an in-frame fusion such that the mutant transcript would create a truncated protein with residues 1 to 209 fused to residues 687 to 929 and lacking the SRF interaction domain. Without the SRF binding region, this truncated protein is nonfunctional and does not act as a dominant-negative mutant on SRF target genes (33, 52).
MRTF-A mutant females are unable to productively nurse their offspring. Although MRTF-A null mice showed no obvious abnormalities, we noticed that the offspring of MRTF-A null females failed to thrive. The pups raised by MRTF-A null females showed growth retardation from postnatal day 4, and none survived beyond 20 days of age (Fig. 2A). The growth retardation of offspring of MRTF-A null females was independent of their genotype, suggesting an abnormality in the mutant mothers rather than the offspring. Indeed, wild-type pups fostered to MRTF-A null females also failed to thrive, whereas MRTF-A null pups fostered to wild-type mothers grew normally (Fig. 2B). MRTF-A-deficient females attended to their young and allowed them to suckle from the nipples, suggesting that they did not exhibit abnormal maternal nurturing behavior. These findings suggested that MRTF-A is required specifically for females to productively nurse their young. We observed the same phenotype with mutant mice in mixed 129SvEv/C57BL6 and isogenic 129SvEv backgrounds, indicating that genetic background did not affect the phenotype.
|
|
Myoepithelial cell defects in MRTF-A mutant mice.
To pinpoint the cell type responsible for the nursing defects of MRTF-A mutant mothers, we examined markers of the different mammary cell types using RT-PCR analysis with RNA samples from mammary tissues of 8-week-old virgins and females at 14 days of pregnancy, 4 days of lactation, 12 days of lactation, and 4 days of involution. Transcripts encoding milk proteins (
-lactalbumin, ß-casein, and whey acidic protein) (3, 41) were expressed normally at all stages in MRTF-A mutant mammary glands (Fig. 4A). The luminal epithelial cell-specific cytoskeletal protein cytokeratin 18 (50) was also expressed at a normal level in the mutants (Fig. 4A). Thus, luminal epithelial cell differentiation and function appeared unperturbed in the mutant mammary glands, and the nursing defect of MRTF-A mutant females is likely caused by defects of mammary myoepithelial cells and milk release.
|
Smooth muscle genes are up-regulated in the mammary glands of wild-type females during the pregnancy-lactation transition (19). There was a slight reduction in expression of smooth muscle genes in mammary tissue from MRTF-A mutant virgins and 14-day-pregnant mice compared to that from wild-type females. However, we observed a pronounced loss of smooth muscle markers in the mammary myoepithelial cells of lactating MRTF-A mutant females (Fig. 4A). The dramatic down-regulation of smooth muscle gene expression in myoepithelial cells from mutant mammary gland was confirmed by in situ hybridization (Fig. 4B).
It is intriguing that the ablation of smooth muscle gene expression was restricted to the lactation phase, while the initial differentiation of mammary myoepithelial cells appeared normal in MRTF-A mutant virgins. MRTF-A and MRTF-B were expressed constantly during the mammary developmental cycle (Fig. 4A), while myocardin gene expression was not detected in mammary tissue. RT-PCR analysis with human mammary epithelial cell line Hs578T and myoepithelial cell line Hs578Bst showed that MRTF-A and MRTF-B are both expressed in these two cell lines (data not shown). Given the functional redundancy of these two transcription factors, it is possible that MRTF-B alone is able to initiate smooth muscle gene expression of mammary myoepithelial cells at the resting stage; however, the rapid proliferation and differentiation of myoepithelial cells during pregnancy and lactation require MRTF-A.
Abnormalities in myoepithelial cell differentiation in MRTF-A mutant mothers.
To further examine the differentiation of myoepithelial cells, we performed immunohistochemistry using antibodies against myoepithelial protein SM
-actin and the epithelial protein cytokeratin 18 (Fig. 5A). CK18 antibody labels the inner layer of epithelial cells of the milk ducts and alveoli, and its expression is comparable between wild-type and MRTF-A mutant animals at all stages examined. SM
-actin-positive myoepithelial cells form a single layer around the ducts. SM
-actin was expressed at a comparable level in wild-type and MRTF-A mutant 8-week-old virgin females (Fig. 5A, a and b). However, during pregnancy, the wild-type myoepithelial cells around the mammary ducts showed a stronger and thicker staining pattern with a stellate shape, while the mutant myoepithelial cells maintained a staining pattern similar to that of 8-week-old virgins (Fig. 5A, c and d). On day 1 of lactation, SM
-actin expression in the mutant appeared similar to that in the wild type (Fig. 5A, e and f). However, SM
-actin eventually decreased during the lactation process in the mutant (Fig. 5A, g to l), and strikingly, during late lactation, the mutant myoepithelial cells showed almost no SM
-actin expression, while the wild-type myoepithelial cells formed a discontinuous, basket-like single layer around the alveolar lumens (Fig. 5A, k and l). However, upon involution (4 days after weaning), the expression of SM
-actin in MRTF-A mutants returned to a level comparable to that of wild-type females (Fig. 5A, o and p). Immunohistochemistry with other smooth muscle proteins, such as SM calponin and SM-myosin heavy chain (MHC), showed similar expression patterns in MRTF-A mutant mammary glands (data not shown), which is consistent with the mRNA expression of these genes.
|
-actin and CK14 indicated that on day 4 of lactation, both of these proteins were still expressed in most of the myoepithelial cells of the MRTF-A mutant, although at a decreased level compared to that in the wild type. On day 10, the expression of these two genes were further reduced, while by day 12, expression of SM
-actin and CK14 was no longer detectable (Fig. 5B). Noticeably, at day 4 of lactation, the cell number around the lumens of the alveoli in mutant mammary glands was similar to that of the wild type, and typically there were three layers of cells, comprising two layers of epithelial cells separated by one layer of myoepithelial cells. In contrast, at day 12 of lactation, the number of cells surrounding the lumens was greatly reduced in the mutant mammary tree, and the walls between adjacent alveolar lumens were composed of only two layers of cells, which resulted in a thin appearance of these walls (Fig. 5C). All these results implied that the myoepithelial cells were ablated during the late lactating stages in MRTF-A mutant females. TUNEL assays, which specifically label the DNA of apoptotic cells, showed no increase in apoptosis in the mutant mammary gland at the resting or pregnant stages or at days 2, 4, 7, and 12 of lactation, while massive apoptosis was detected in the mutant mammary gland at day 10 of lactation. The mutant mammary gland showed an apoptotic rate during involution that was similar to that of the wild type (Fig. 6A and B).
|
-actin. About 50% of the cells that underwent apoptosis at day 10 of lactation in the mutant were SM
-actin positive, while in the involuting mammary glands of both wild-type and mutant animals, less than 10% of apoptotic cells were SM
-actin positive (Fig. 6C; Table 1). These data suggest that numerous myoepithelial cells die during late lactation and that due to severe milk accumulation, the mutant mammary gland undergoes involution to some extent and a number of epithelial cells also die. We speculate that the residual smooth muscle proteins present during early lactation were adequate to maintain a low level of milk ejection that allowed the survival of offspring of the MRTF-A mutant females. However, during the late phase of lactation, when the myoepithelial cells were almost completely ablated in the mutant mammary tree, milk could not be ejected and the milk stasis induced premature involution, resulting in starvation of the offspring.
|
Involution is also associated with characteristic changes in expression of a battery of genes, especially those related to cell death and immune responses, as shown recently by systematic microarray analysis (8, 47). To further examine whether involution-related genes were induced by milk stasis in MRTF-A mutant mammary glands, we analyzed the expression of a series of genes that have been shown to be involved in involution by semiquantitative RT-PCR (Fig. 6D). Signal transducer and activator of transcription 3 (STAT3) is a key regulator of mammary involution involved in both programmed cell death and the acute phase response (6, 17). STAT3 expression was comparable in wild-type and MRTF-A mutant mammary glands at both the mRNA and protein levels during different stages of the mammary cycle. It is known that STAT3 is highly phosphorylated upon involution. The phosphorylation status of Stat3 was examined by Western blotting using an antibody against phosphorylated STAT3, which showed that indeed Stat3 is hyper-phosphorylated in the mutant mammary gland during late lactation (Fig. 6E). The CEBP
gene, a target of STAT3, is also up-regulated during lactation. Several other involution-related genes were up-regulated during lactation in the mutant mammary tissue. These genes include monocyte differentiation antigen CD14, serum amyloid A2, and the neutrophilic granulocyte marker LRG1 (leucine-rich alpha 2-glycoprotein 1), which are all involved in immune responses; IGFBP5 (insulin-like growth factor binding protein 5), which is important for the induction of apoptosis; and tyro3 (protein-tyrosine kinase 3), whose function in mammary involution has not been fully defined. Interestingly, the gene encoding lipopolysaccharide binding protein, which is involved in the acute phase response and also a target of STAT3 (47), was expressed at a normal level in MRTF-A mutants. These data indicate that milk stasis induces immune responses and up-regulation of certain involution genes in MRTF-A mutant mammary gland, while the hormonal level, which is sustained by continued suckling of the pups, controls milk secretion and the expression of other involution-related genes.
It is interesting that myoepithelial cell gene expression returned to a relatively normal level a few days after weaning of the pups. To examine whether more myoepithelial cells were generated by excessive proliferation, double immunostaining with antibodies against PCNA and SM
-actin was performed. Proliferation rates were not disturbed during pregnancy and lactation in the mutant mammary gland (data not shown). However, during involution, the overall proliferation rate was slightly higher in the mutant, and more importantly, there was a significant number of proliferating cells that were SM
-actin positive in the mutant, suggesting that new myoepithelial cells may be generated from progenitor cells after weaning (Fig. 6F; Table 1).
| DISCUSSION |
|---|
|
|
|---|
Myoepithelial development. Myoepithelial cells are found within the secretory and ductal portions of most glands. Their contractile function, which is controlled by hormonal and neural signals, is essential for ductal secretion. Myoepithelial cells also transport metabolites to secretory cells and provide structural integrity to glandular tissues through their association with the basement membrane. The ultrastructure, gene expression pattern, and contractile properties of myoepithelial cells are strikingly similar to those of SMCs. However, in contrast to SMCs, which are derived from mesodermal precursors and neural crest cells, myoepithelial cells of the mammary gland are derived from ectoderm. To our knowledge, the molecular mechanisms responsible for myoepithelial cell differentiation have not been previously defined.
The mammary ductal tree forms normally in MRTF-A mutant mice, but myoepithelial cells fail to differentiate upon lactation, as shown by the lack of expression of smooth muscle contractile protein genes such as those encoding SM
-actin, SM MHC, and SM caldesmon during lactation. As a result, mutant mothers are unable to release their milk. Oxytocin, a neurohypophyseal hormone essential for stimulating myoepithelial cell contraction and milk ejection, is expressed normally in MRTF-A mutants (data not shown). The oxytocin receptor is exclusively expressed in myoepithelial cells within the mammary gland (12, 13). Expression of oxytocin receptor transcripts is unchanged in the mutant mammary gland during early lactation (day 4), when the myoepithelium-specific smooth muscle proteins and cytokeratins are already down-regulated. At lactating day 12, oxytocin receptor expression is diminished since the myoepithelial cells are lost due to excessive apoptosis. Thus, it is unlikely that defective oxytocin circulation or signaling contributes to the nursing deficiency of MRTF-A mutant females.
It is curious that the phenotype of MRTF-A mutant mice is so restricted to myoepithelial cells of the mammary gland. Myoepithelial cells are also associated with salivary and lacrimal glands, but we did not detect abnormalities in these glandular tissues, raising the possibility that other members of the myocardin family may substitute for MRTF-A function in those tissues. In this regard, it is interesting to note that MRTF-B is expressed at normal levels in mammary glands from MRTF-A mutant females. MRTF-A and -B are also expressed in the mammary epithelial and myoepithelial cell lines Hs578T and Hs578Bst, respectively. This could suggest that MRTF-A is uniquely required for differentiation of mammary myoepithelial cells or that the loss of MRTF-A reduces the level of myocardin family members below a critical threshold required for myoepithelial cell differentiation. It is also interesting that the myoepithelial cell defects of MRTF-A mutant mice are restricted to pregnancy and lactating stages, while smooth muscle gene expression is normal in the resting mammary gland. It is possible that during the resting stage, MRTF-B is able to take the place of MRTF-A and sustain the smooth muscle program, while during pregnancy and lactation, when extensive proliferation and differentiation of myoepithelial cells is necessary, MRTF-B cannot compensate for the loss of MRTF-A. It will also be interesting to examine whether transcriptional activities of MRTF-A and -B are differentially regulated by female hormones during mammary development.
MRTF-A is required for maintenance of differentiation and survival of mammary myoepithelial cells. In the lactating mammary glands of MRTF-A mutant females, not only the smooth muscle genes but also other myoepithelial cell-specific genes, such as the cytokeratin 14 and CALLA genes, were down-regulated. There are no conserved SRF binding sites within 40 kb upstream of the transcription initiation sites of these genes, and there have been no reports that expression of these genes might be under the control of SRF. Since smooth muscle structural proteins and cytokeratins together compose the cytoskeletal structure of these cells, we speculate that loss of smooth muscle proteins leads to the dispensability of cytokeratins and in turn to degradation of these proteins or repression of their expression, although we cannot exclude the possibility that MRTF-A has partners other than SRF that control the expression of these myoepithelium-specific genes. There was a dramatic increase of apoptotic cells specifically at lactating day 10; at day 12 the alveolar walls were much thinner and composed of fewer cells, although the overall alveolar structures were still maintained. Notably, the decrease in expression of smooth muscle and myoepithelium-specific genes preceded apoptotic cell death. Thus, the impaired function of myoepithelial cells resulting from a failure in expression of smooth muscle and myoepithelium-specific genes appears to result in programmed cell death of myoepithelial cells.
It has been previously reported that failure of milk ejection promotes mammary involution (39, 51). In mice in which milk removal is disrupted by teat sealing, milk synthesis declines, and programmed cell death can proceed without disruption of the alveolar structure, although gene expression profiling has not been performed with these mice (24). Milk trapped within the alveoli was observed in MRTF-A mutant mammary glands from early lactation. However, excessive apoptosis was not detected until day 10 of lactation, and unlike in normal involution, myoepithelial cells account for a large fraction of the apoptotic cells. Moreover, the lobular-alveolar structure of the mutant mammary gland maintained the lactating appearance throughout lactation, and milk protein expression was sustained at a normal level. The reason mutant epithelial cells still produced milk and maintained their integrity might be that trace amounts of smooth muscle contractile proteins were still able to release a small amount of milk, as suggested by the survival of pups until late lactation, and that the stress of milk accumulation was not as severe as that resulting from weaning or sealing the teats. However, the stress was able to induce an immune response, and at the level of gene transcription, some, but not all, involution-related genes were up-regulated. We cannot exclude the possibility that MRTF-A has an anti-involution or anti-inflammatory effect; however, given the clear myoepithelial defects and milk accumulation we observed, it is highly likely that the up-regulation of the involution genes is secondary to milk stasis.
Regulation of cell migration and cytoskeletal development by the myocardin family and SRF. We showed previously that myocardin gene null mice die at E10.5 from an apparent lack of differentiated SMCs (26). However, the interpretation of this mutant phenotype was complicated by the fact that the myocardin gene is expressed in only a small subset of SMCs at this stage of development. In addition, myocardin gene mutant embryos displayed abnormalities in yolk sac development, making it difficult to distinguish whether the effects of myocardin gene deletion on embryonic vascular development are primary or secondary to yolk sac abnormalities.
A null mutation in the MRTF-B gene also results in embryonic lethality at
E12.5 due to a spectrum of cardiovascular defects (38). Thus, each member of the myocardin gene family is required for the activation of smooth muscle gene expression, but each is uniquely required in a different cell type at a different developmental stage. It will eventually be interesting to generate mice with different combinations of mutations of the myocardin family genes in order to determine whether there are cell types in which they are functionally redundant and whether there might be alternative pathways leading to smooth muscle gene expression in a subset of cell types.
MRTF-A has been shown to mediate the effects of Rho signaling and changes in the actin cytoskeleton on SRF-dependent transcription (21, 33). Mice overexpressing a dominant-negative form of MRTF-A in skeletal muscle showed skeletal myopathy and hypoplasia (25). Similarly, a dominant-negative mutant of MRTF-B/MKL2 inhibits differentiation of skeletal muscle cells in vitro (44). Remarkably, however, MRTF-A mutant mice display no obvious abnormalities in skeletal, cardiac, or smooth muscle, presumably due to the redundancy between MRTF-A and MRTF-B.
Implications.
In addition to their role in milk secretion, myoepithelial cells have been suggested to possess tumor suppression activities (1, 22, 48, 49). Myoepithelial cells produce anti-invasive protease inhibitors and antiangiogenic molecules, such as the protease nexin II,
1-antitrypsin, tissue inhibitor of metalloproteinase 1, thrombospondin 1, and soluble basic fibroblast growth factor receptor (35, 45, 46). Thus, myoepithelial cells can induce growth arrest and apoptosis of breast carcinoma cells by interfering with the invasive behavior of tumor cells and inhibiting angiogenesis. Given the roles of SRF and MRTFs in controlling expression of growth responsive genes, such as c-fos and egr-1 (5, 37), it will be of interest to determine whether MRTF-A plays a role in breast cancer.
.
| ACKNOWLEDGMENTS |
|---|
This work was supported by grants from the National Institutes of Health, the Donald W. Reynolds Cardiovascular Clinical Research Center, and the Robert A. Welch Foundation to E.N.O.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Arsenian, S., B. Weinhold, M. Oelgeschlager, U. Ruther, and A. Nordheim. 1998. Serum response factor is essential for mesoderm formation during mouse embryogenesis. EMBO J. 17:6289-6299.[CrossRef][Medline]
3. Burdon, T., L. Sankaran, R. J. Wall, M. Spencer, and L. Hennighausen. 1991. Expression of a whey acidic protein transgene during mammary development. Evidence for different mechanisms of regulation during pregnancy and lactation. J. Biol. Chem. 266:6909-6914.
4. Cen, B., A. Selvaraj, R. C. Burgess, J. K. Hitzler, Z. Ma, S. W. Morris, and R. Prywes. 2003. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes. Mol. Cell. Biol. 23:6597-6608.
5. Cen, B., A. Selvaraj, and R. Prywes. 2004. Myocardin/MKL family of SRF coactivators: key regulators of immediate early and muscle specific gene expression. J. Cell. Biochem. 93:74-82.[CrossRef][Medline]
6. Chapman, R. S., P. Lourenco, E. Tonner, D. Flint, S. Selbert, K. Takeda, S. Akira, A. R. Clarke, and C. J. Watson. 2000. The role of Stat3 in apoptosis and mammary gland involution. Conditional deletion of Stat3. Adv. Exp. Med. Biol. 480:129-138.[Medline]
7. Chen, J., C. M. Kitchen, J. W. Streb, and J. M. Miano. 2002. Myocardin: a component of a molecular switch for smooth muscle differentiation. J. Mol. Cell. Cardiol. 34:1345-1356.[CrossRef][Medline]
8. Clarkson, R. W., M. T. Wayland, J. Lee, T. Freeman, and C. J. Watson. 2004. Gene expression profiling of mammary gland development reveals putative roles for death receptors and immune mediators in post-lactational regression. Breast Cancer Res. 6:R92-R109.[CrossRef][Medline]
9. Crowley, W. R., and W. E. Armstrong. 1992. Neurochemical regulation of oxytocin secretion in lactation. Endocr. Rev. 13:33-65.[CrossRef][Medline]
10. Deugnier, M. A., E. P. Moiseyeva, J. P. Thiery, and M. Glukhova. 1995. Myoepithelial cell differentiation in the developing mammary gland: progressive acquisition of smooth muscle phenotype. Dev. Dyn. 204:107-117.[Medline]
11. Du, K. L., H. S. Ip, J. Li, M. Chen, F. Dandre, W. Yu, M. M. Lu, G. K. Owens, and M. S. Parmacek. 2003. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol. Cell. Biol. 23:2425-2437.
12. Gimpl, G., and F. Fahrenholz. 2001. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 81:629-683.
13. Gould, B. R., and H. H. Zingg. 2003. Mapping oxytocin receptor gene expression in the mouse brain and mammary gland using an oxytocin receptor-LacZ reporter mouse. Neuroscience 122:155-167.[CrossRef][Medline]
14. Gusterson, B. A., P. Monaghan, R. Mahendran, J. Ellis, and M. J. O'Hare. 1986. Identification of myoepithelial cells in human and rat breasts by anti-common acute lymphoblastic leukemia antigen antibody A12. JNCI 77:343-349.[Medline]
15. Hennighausen, L., and G. W. Robinson. 1998. Think globally, act locally: the making of a mouse mammary gland. Genes Dev. 12:449-455.
16. Herring, B. P., and A. F. Smith. 1997. Telokin expression in A10 smooth muscle cells requires serum response factor. Am. J. Physiol. 272:C1394-C1404.[Medline]
17. Humphreys, R. C., B. Bierie, L. Zhao, R. Raz, D. Levy, and L. Hennighausen. 2002. Deletion of Stat3 blocks mammary gland involution and extends functional competence of the secretory epithelium in the absence of lactogenic stimuli. Endocrinology 143:3641-3650.
18. Imagawa, W., G. K. Bandyopadhyay, and S. Nandi. 1990. Regulation of mammary epithelial cell growth in mice and rats. Endocr. Rev. 11:494-523.[Medline]
19. Jin, H. S., S. Umemura, T. Iwasaka, and R. Y. Osamura. 2000. Alterations of myoepithelial cells in the rat mammary gland during pregnancy, lactation and involution, and after estradiol treatment. Pathol. Int. 50:384-391.[CrossRef][Medline]
20. Kim, S., H. S. Ip, M. M. Lu, C. Clendenin, and M. S. Parmacek. 1997. A serum response factor-dependent transcriptional regulatory program identifies distinct smooth muscle cell sublineages. Mol. Cell. Biol. 17:2266-2278.[Abstract]
21. Kuwahara, K., T. Barrientos, G. C. Pipes, S. Li, and E. N. Olson. 2005. Muscle-specific signaling mechanism that links actin dynamics to serum response factor. Mol. Cell. Biol. 25:3173-3181.
22. Lakhani, S. R., and M. J. O'Hare. 2001. The mammary myoepithelial cellCinderella or ugly sister? Breast Cancer Res. 3:1-4.[CrossRef][Medline]
23. Li, L., Z. Liu, B. Mercer, P. Overbeek, and E. N. Olson. 1997. Evidence for serum response factor-mediated regulatory networks governing SM22alpha transcription in smooth, skeletal, and cardiac muscle cells. Dev. Biol. 187:311-321.[CrossRef][Medline]
24. Li, M., X. Liu, G. Robinson, U. Bar-Peled, K. U. Wagner, W. S. Young, L. Hennighausen, and P. A. Furth. 1997. Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc. Natl. Acad. Sci. USA 94:3425-3430.
25. Li, S., M. P. Czubryt, J. McAnally, R. Bassel-Duby, J. A. Richardson, F. F. Wiebel, A. Nordheim, and E. N. Olson. 2005. Requirement for serum response factor for skeletal muscle growth and maturation revealed by tissue-specific gene deletion in mice. Proc. Natl. Acad. Sci. USA 102:1082-1087.
26. Li, S., D. Z. Wang, Z. Wang, J. A. Richardson, and E. N. Olson. 2003. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc. Natl. Acad. Sci. USA 100:9366-9370.
27. Lilly, B., E. N. Olson, and M. C. Beckerle. 2001. Identification of a CArG box-dependent enhancer within the cysteine-rich protein 1 gene that directs expression in arterial but not venous or visceral smooth muscle cells. Dev. Biol. 240:531-547.[CrossRef][Medline]
28. Ma, Z., S. W. Morris, V. Valentine, M. Li, J. A. Herbrick, X. Cui, D. Bouman, Y. Li, P. K. Mehta, D. Nizetic, Y. Kaneko, G. C. Chan, L. C. Chan, J. Squire, S. W. Scherer, and J. K. Hitzler. 2001. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat. Genet. 28:220-221.[CrossRef][Medline]
29. Mack, C. P., and G. K. Owens. 1999. Regulation of smooth muscle alpha-actin expression in vivo is dependent on CArG elements within the 5' and first intron promoter regions. Circ. Res. 84:852-861.
30. Manabe, I., and G. K. Owens. 2001. CArG elements control smooth muscle subtype-specific expression of smooth muscle myosin in vivo. J. Clin. Investig. 107:823-834.[Medline]
31. Mercher, T., M. B. Coniat, R. Monni, M. Mauchauffe, F. N. Khac, L. Gressin, F. Mugneret, T. Leblanc, N. Dastugue, R. Berger, and O. A. Bernard. 2001. Involvement of a human gene related to the Drosophila spen gene in the recurrent t(1;22) translocation of acute megakaryocytic leukemia. Proc. Natl. Acad. Sci. USA 98:5776-5779.
32. Miano, J. M., M. J. Carlson, J. A. Spencer, and R. P. Misra. 2000. Serum response factor-dependent regulation of the smooth muscle calponin gene. J. Biol. Chem. 275:9814-9822.
33. Miralles, F., G. Posern, A. I. Zaromytidou, and R. Treisman. 2003. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113:329-342.[CrossRef][Medline]
34. Neville, M. C., T. B. McFadden, and I. Forsyth. 2002. Hormonal regulation of mammary differentiation and milk secretion. J. Mammary Gland Biol. Neoplasia 7:49-66.[CrossRef][Medline]
35. Nguyen, M., M. C. Lee, J. L. Wang, J. S. Tomlinson, Z. M. Shao, M. L. Alpaugh, and S. H. Barsky. 2000. The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. Oncogene 19:3449-3459.[CrossRef][Medline]
36. Nishimori, K., L. J. Young, Q. Guo, Z. Wang, T. R. Insel, and M. M. Matzuk. 1996. Oxytocin is required for nursing but is not essential for parturition or reproductive behavior. Proc. Natl. Acad. Sci. USA 93:11699-11704.
37. Norman, C., M. Runswick, R. Pollock, and R. Treisman. 1988. Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element. Cell 55:989-1003.[CrossRef][Medline]
38. Oh, J., J. A. Richardson, and E. N. Olson. 2005. Requirement of myocardin-related transcription factor-B for remodeling of branchial arch arteries and smooth muscle differentiation. Proc. Natl. Acad. Sci. USA 102:15122-15127.
39. Quarrie, L. H., C. V. Addey, and C. J. Wilde. 1996. Programmed cell death during mammary tissue involution induced by weaning, litter removal, and milk stasis. J. Cell. Physiol. 168:559-569.[CrossRef][Medline]
40. Richert, M. M., K. L. Schwertfeger, J. W. Ryder, and S. M. Anderson. 2000. An atlas of mouse mammary gland development. J. Mammary Gland Biol. Neoplasia 5:227-241.[CrossRef][Medline]
41. Rosen, J. M., J. R. Rodgers, C. H. Couch, C. A. Bisbee, Y. David-Inouye, S. M. Campbell, and L. Y. Yu-Lee. 1986. Multihormonal regulation of milk protein gene expression. Ann. N. Y. Acad. Sci. 478:63-76.[Medline]
42. Sasazuki, T., T. Sawada, S. Sakon, T. Kitamura, T. Kishi, T. Okazaki, M. Katano, M. Tanaka, M. Watanabe, H. Yagita, K. Okumura, and H. Nakano. 2002. Identification of a novel transcriptional activator, BSAC, by a functional cloning to inhibit tumor necrosis factor-induced cell death. J. Biol. Chem. 277:28853-28860.
43. Seagroves, T. N., S. Krnacik, B. Raught, J. Gay, B. Burgess-Beusse, G. J. Darlington, and J. M. Rosen. 1998. C/EBPbeta, but not C/EBPalpha, is essential for ductal morphogenesis, lobuloalveolar proliferation, and functional differentiation in the mouse mammary gland. Genes Dev. 12:1917-1928.
44. Selvaraj, A., and R. Prywes. 2003. Megakaryoblastic leukemia-1/2, a transcriptional co-activator of serum response factor, is required for skeletal myogenic differentiation. J. Biol. Chem. 278:41977-41987.
45. Shao, Z. M., M. Nguyen, M. L. Alpaugh, J. T. O'Connell, and S. H. Barsky. 1998. The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis. Exp. Cell Res. 241:394-403.[CrossRef][Medline]
46. Shao, Z. M., W. J. Radziszewski, and S. H. Barsky. 2000. Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. Cancer Lett. 157:133-144.[CrossRef][Medline]
47. Stein, T., J. S. Morris, C. R. Davies, S. J. Weber-Hall, M. A. Duffy, V. J. Heath, A. K. Bell, R. K. Ferrier, G. P. Sandilands, and B. A. Gusterson. 2004. Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. Breast Cancer Res. 6:R75-R91.[CrossRef][Medline]
48. Sternlicht, M. D., and S. H. Barsky. 1997. The myoepithelial defense: a host defense against cancer. Med. Hypotheses 48:37-46.[CrossRef][Medline]
49. Sternlicht, M. D., P. Kedeshian, Z. M. Shao, S. Safarians, and S. H. Barsky. 1997. The human myoepithelial cell is a natural tumor suppressor. Clin. Cancer Res. 3:1949-1958.[Abstract]
50. Taylor-Papadimitriou, J., M. Stampfer, J. Bartek, A. Lewis, M. Boshell, E. B. Lane, and I. M. Leigh. 1989. Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. J. Cell Sci. 94:403-413.
51. Wagner, K. U., W. S. Young III, X. Liu, E. I. Ginns, M. Li, P. A. Furth, and L. Hennighausen. 1997. Oxytocin and milk removal are required for post-partum mammary-gland development. Genes Funct. 1:233-244.[Medline]
52. Wang, D., P. S. Chang, Z. Wang, L. Sutherland, J. A. Richardson, E. Small, P. A. Krieg, and E. N. Olson. 2001. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 105:851-862.[CrossRef][Medline]
53. Wang, D. Z., S. Li, D. Hockemeyer, L. Sutherland, Z. Wang, G. Schratt, J. A. Richardson, A. Nordheim, and E. N. Olson. 2002. Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc. Natl. Acad. Sci. USA 99:14855-14860.
54. Wang, D. Z., and E. N. Olson. 2004. Control of smooth muscle development by the myocardin family of transcriptional coactivators. Curr. Opin. Genet. Dev. 14:558-566.[CrossRef][Medline]
55. Wang, Z., D. Z. Wang, D. Hockemeyer, J. McAnally, A. Nordheim, and E. N. Olson. 2004. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 428:185-189.[CrossRef][Medline]
56. Wang, Z., D. Z. Wang, G. C. Pipes, and E. N. Olson. 2003. Myocardin is a master regulator of smooth muscle gene expression. Proc. Natl. Acad. Sci. USA 100:7129-7134.
57. Warburton, M. J., D. Mitchell, E. J. Ormerod, and P. Rudland. 1982. Distribution of myoepithelial cells and basement membrane proteins in the resting, pregnant, lactating, and involuting rat mammary gland. J. Histochem. Cytochem. 30:667-676.[Abstract]
58. Yoshida, T., S. Sinha, F. Dandre, B. R. Wamhoff, M. H. Hoofnagle, B. E. Kremer, D. Z. Wang, E. N. Olson, and G. K. Owens. 2003. Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ. Res. 92:856-864.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||